Resources from the same session
524O - Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours
Presenter: Lillian Siu
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
525O - A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
Presenter: Geoffrey Ku
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
526O - High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
Presenter: Benoit Rousseau
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
527O - CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study
Presenter: Victor Moreno Garcia
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
528O - CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
Presenter: Antoine Hollebecque
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 524O, 525O and 526O
Presenter: Antoine Italiano
Session: Proffered Paper - Developmental therapeutics
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Christophe Massard
Session: Proffered Paper - Developmental therapeutics
Resources:
Webcast
Q&A and live discussion
Presenter: Christophe Massard
Session: Proffered Paper - Developmental therapeutics
Resources:
Webcast